Radix Labs
Making an operating system for biology by enabling biologists to describe their process at a high level to automatically program their lab robots for them.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
$4.0m | Series A | ||
| Total Funding | 000k | ||
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Radix.bio is a biotech software company that revolutionizes laboratory management by enabling scientists to design, execute, and analyze multiple experiments more efficiently and reliably. The platform serves academic institutions, research organizations, and biotech companies, providing a digital, future-proof format for data and protocols that ensures full reproducibility. Radix.bio operates in the biotech and life sciences market, leveraging the theory of constraints to automate complex experimental processes. The business model is likely subscription-based, offering its software as a service (SaaS) to clients who benefit from streamlined lab operations and enhanced scientific outcomes. Revenue is generated through subscription fees, potentially supplemented by premium features or enterprise solutions.
Keywords: biotech, software, experiments, reproducibility, automation, SaaS, lab management, life sciences, research, data protocols.